Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bayer Bids To Be A Winner In Cell & Gene Therapy

Adopts Four-Pillar Strategy

Executive Summary

The last six weeks have seen the acquisition of AskBio, the launch of a dedicated cell and gene therapy unit and a CAR-T pact with Atara. Bayer is taking the space very seriously.

You may also be interested in...



Big Year Ahead For New Vir CEO De Backer

Having played a pivotal role in changing pharma strategy at Bayer, Marianne De Backer tells Scrip about her goal to turn Vir into an infectious disease powerhouse as the firm prepares for critical Phase II data readouts in hepatitis B and D, as well as flu.

Pharma Spreads Its Bets On Multiple Modalities In Advanced Products

Companies such as Novartis, Roche or Takeda are heavily invested in the advanced therapeutics field, usually spreading their bets across multiple modalities. The remaining challenges offer opportunities for the next wave of innovation to transform the field once again and make a dent in the larger market of common diseases and solid tumors.

Xarelto Still Climbs As Bayer Touts Successor

Bayer's pharmaceuticals chief Stefan Oelrich says that sales of treatments in the areas of ophthalmology, women’s healthcare and radiology have risen sharply, recovering from the effects of the COVID-19 pandemic.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC143449

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel